SGMT: Sagimet Biosciences Company Short-Term Debt

Symbol and logo of brand Sagimet Biosciences (SGMT)

Sagimet Biosciences (SGMT) operates without steady cash inflows as it focuses on developing drugs for the therapy of liver pathologies. The current debt load stands at 0.00, confirming a stage of active cash burn prior to the commercial launch of products. This price chart complements data regarding the implementation of AI systems for molecular modeling and the use of automated dispensing stations in laboratories.

SGMT (Sagimet Biosciences, Inc.) Company Short-Term Debts history from 02/21/2024 to 11/01/2026

SGMT (Sagimet Biosciences Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Sagimet Biosciences Inc.|SGMT - Fair Value Consensus
- market capitalization information:
Market Value Sagimet Biosciences Inc.|SGMT - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Sagimet Biosciences|SGMT - Book Capitalization|Market Cap to Net Assets Ratio sagimet.com|SGMT - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Sagimet Biosciences|SGMT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Sagimet Biosciences|SGMT - Company Cumulative Debt|Debt to Book Value Sagimet Biosciences Inc.|SGMT - Amount of Long-Term Liabilities|Company Short-Term Debts Sagimet Biosciences|Quick Ratio sagimet.com
- net income and valuation multiples indicators:
SGMT - Company Net Income
Basic company analysis:Sagimet Biosciences Inc. - SGMT
Mass-produced product of Sagimet Biosciences Inc

Sagimet Biosciences (SGMT) is investing in the development of treatments for acne and fatty liver disease to diversify its medical risks. This strategy requires significant capital, which is reflected in the total volume of loans maturing within one year. This metric measures the short-term debt load, determining the issuer's financial stability and liquidity. Reducing liabilities minimizes default risks but may limit the pace of expansion. By analyzing short-term balance sheet obligations, an investor can discern the real cost of current stability.

Who Sagimet Biosciences competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debt Lipocine Inc. LPCN|Short-Term Debt Volume Matinas BioPharma Holdings, Inc. (MTNB)|Spruce Biosciences - Company Short-Term Debts|GLTO - Company Short-Term Debts|CTCX: Company Short-Term Debts|Short-Term Indebtedness Lumos Therapeutics LUMO|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|radiuspharm.com (RDUS) - Short-Term Debt Volume